Wednesday, October 22, 2014

Roth adds MEI Pharma to Focus List, ups price target to $22

Roth adds MEI Pharma to Focus List, ups price target to $22

October 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis writes that MEI is well positioned with its lead oral HDAC inhibitor, pracinostat, for the treatment of acute myeloid leukemia (AML) and […]

Roth resumes coverage of XOMA at buy

Roth resumes coverage of XOMA at buy

October 10, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $9 price target. The stock closed at $3.72 on Thursday. “We believe data lock is imminent on the ongoing Phase 3 EYEGUARD-B study of gevokizumab in Behçet’s disease uveitis, with top-line data expected around year-end,” writes analyst Ed Arce. “Given […]

Roth starts ContraFect at buy

Roth starts ContraFect at buy

October 6, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of ContraFect (NASDAQ:CFRX) with a “buy” rating and $14 price target. The stock closed at $3.46 on Friday. The company completed an IPO in August. Its lead therapeutic approach is using lysins from bacteriophage as a potential and significant new option for anti-microbial approaches. “We believe the current […]

Titan Pharmaceuticals prices offering of units

Titan Pharmaceuticals prices offering of units

October 3, 2014 by · Leave a Comment 

Tweet Titan Pharmaceuticals (OTCBB:TTNP) has priced a public offering of 21 million units at a price of 50 cents a unit, with each unit consisting of one common share and 0.75 of a warrant. Titan expects to receive gross proceeds of $10.5-million from the offering, before deducting underwriting discounts, commissions and other related expenses. Roth […]

Roth starts BioBlast Pharma at buy

Roth starts BioBlast Pharma at buy

August 25, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and $15 price target. The stock closed at $7.68 on Friday. BioBlast has three proprietary platform technologies to treat rare and ultra-rare genetic diseases. They include Cabaletta for mutant protein stabilization, BBrm for induction of read-through (bypass) of early mutant DNA stop […]

Roth starts iRadimed at buy

Roth starts iRadimed at buy

August 11, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of iRadimed (NASDAQ:IRMD) with a “buy” rating and $14 price target. The stock finished at $11.03 on Friday. iRadimed’s mRidium 3860+ pump system is a unique MRI-safe, non-magnetic IV infusion pump that offers an effective way to safely and accurately deliver necessary IV fluids to critically ill and […]

Roth starts Sucampo at buy

Roth starts Sucampo at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Sucampo Pharmaceuticals (NASDAQ:SCMP) with a “buy” rating and price target of $9. The shares were quoted at $6 in early trading on Friday. “Our positive thesis on Sucampo is based on three tenets,” writes analyst Ed Arce. On Aug. 5, new CEO, Peter Greenleaf, will announce his […]

Roth starts Alcobra Pharma at buy

Roth starts Alcobra Pharma at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Alcobra Pharma (NASDAQ:ADHD) with a “buy” rating and $40 price target. The stock closed at $18.02 on Thursday. Alcobra Pharma’s lead product, MDX, an extended release formulation of Metadoxin, is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). MDX could also have a significant […]

Roth upgrades Prosensa Therapeutic to buy

Roth upgrades Prosensa Therapeutic to buy

July 28, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded Prosensa Therapeutic NV (NASDAQ:RNA) to “buy,” with a $17 price target, reflecting evolving data in the treatment of Duchenne muscular dystrophy (DMD) and a conciliatory regulatory environment. The stock closed at $9.65 on Friday. Prosensa’s drisapersen treatment for DMD failed a Phase 3 trial last fall, prompting partner GlaxoSmithKline […]

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

Next Page »

Email Newsletters with Constant Contact
Google+